Psychopharmacology with Children and Adolescents

Approximately 1 in 5 children/adolescents has a diagnosable mental health condition. Rates of anxiety and depression have particularly been increasing, with the American Academy of Pediatrics declaring a national mental health emergency in this patient population in 2021. There are fewer evidence-based, FDA-approved psychotropic medication options available for pediatric patients, leading to frequent “off-label” use. Children may also be more vulnerable to adverse effects from medication compared to adults. Front-line healthcare workers, such as social workers, are in a prime position to monitor patients who are taking psychotropic medications for symptom improvement and adverse effects to aid in appropriate team-based care.[Requirement for Child & Adolescent Mental Health Certificate Program]

This webinar does not have any offerings for this semester.